Pathology, research and practice · 2025
Quantitative and spatial distribution characteristics of CD66b+ tumor-associated neutrophils in metaplastic and non-metaplastic triple-negative breast cancer treated with neoadjuvant therapy and their prognostic significance.
СтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Xie Ting, Huang Aoling, Luo Bin, Yan Honglin, Zhang Hongfeng, Chen Shuaijun, Chen Zhongtao, Jin Tian, Yuan Jingping
Аннотация
PURPOSE: This study aimed to compare the density and spatial distribution of tumor-associated neutrophils (TANs) in metaplastic breast cancer (MpBC) and non-metaplastic triple-negative breast cancer (TNBC) patients before neoadjuvant chemotherapy (NACT) to identify prognostic biomarkers and therapeutic implications.
METHODS: We conducted a retrospective analysis of patients with MpBC and non-metaplastic TNBC both treated with NACT from three hospitals. CD66b+ TANs were quantified and spatially mapped using an artificial intelligence (AI) -based positive cell classifier. Clinicopathological characteristics were compared between the two groups. Statistical analyses were used to assess the prognostic value of TANs and their predictive value in NACT.
RESULTS: Significant differences were observed between MpBC and non-metaplastic TNBC patients in age, tumor size, Ki-67 expression, residual cancer burden grade, pathologic complete remission (pCR) rate, disease-free survival (DFS), CD66b+ TAN density, and spatial distribution. No MpBC patients achieved pCR, whereas 30.8 % of non-metaplastic TNBC patients did. In MpBC, larger tumor size and stromal-predominant CD66b+ TAN distribution were associated with poorer prognosis. In non-metaplastic TNBC, tumor size > 2 cm, androgen receptor positivity, and high CD66b+ TAN density correlated with lower pCR rates, while tumor size > 2 cm, lymph node positivity, and elevated CD66b+ TAN density were linked to worse DFS.
CONCLUSION: CD66b+ TANs might serve as a potential prognostic biomarker in MpBC and non-metaplastic TNBC following NACT, and their density and spatial distribution also contributed insights into the prognosis of the patients.
METHODS: We conducted a retrospective analysis of patients with MpBC and non-metaplastic TNBC both treated with NACT from three hospitals. CD66b+ TANs were quantified and spatially mapped using an artificial intelligence (AI) -based positive cell classifier. Clinicopathological characteristics were compared between the two groups. Statistical analyses were used to assess the prognostic value of TANs and their predictive value in NACT.
RESULTS: Significant differences were observed between MpBC and non-metaplastic TNBC patients in age, tumor size, Ki-67 expression, residual cancer burden grade, pathologic complete remission (pCR) rate, disease-free survival (DFS), CD66b+ TAN density, and spatial distribution. No MpBC patients achieved pCR, whereas 30.8 % of non-metaplastic TNBC patients did. In MpBC, larger tumor size and stromal-predominant CD66b+ TAN distribution were associated with poorer prognosis. In non-metaplastic TNBC, tumor size > 2 cm, androgen receptor positivity, and high CD66b+ TAN density correlated with lower pCR rates, while tumor size > 2 cm, lymph node positivity, and elevated CD66b+ TAN density were linked to worse DFS.
CONCLUSION: CD66b+ TANs might serve as a potential prognostic biomarker in MpBC and non-metaplastic TNBC following NACT, and their density and spatial distribution also contributed insights into the prognosis of the patients.